Milestone Pharmaceuticals Inc. Common Shares (MIST) Stock
NASDAQ · MIST
Key stats
- Market cap
- $82.44M
- Price / Earnings ratio
- -1.0x
- EPS (TTM)
- -$0.68
- Volume
- Loading
- 52-week high
- $3.06
- 52-week low
- $0.63
Source: third-party data provider, as of November 13, 2026
Compare with MIST
Recent news

MarketBeat
Milestone Pharmaceuticals Q2 Earnings Call Highlights
MISTAugust 12, 2026
MarketBeat
Milestone Pharmaceuticals Q2 Earnings Call Highlights
MIST

Zacks Investment Research
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
MISTAugust 12, 2026
Zacks Investment Research
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
MIST

Zacks Investment Research
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
MISTJuly 29, 2026
Zacks Investment Research
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
MIST

MarketBeat
Milestone Pharmaceuticals Q1 Earnings Call Highlights
MISTMay 13, 2026
MarketBeat
Milestone Pharmaceuticals Q1 Earnings Call Highlights
MIST
Technical indicators
- RSI 14
- 40.73
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.03
- MACD histogram
- 0.00
- SMA 50
- $0.83
- Price below SMA 50
- EMA 50
- $0.83
- Price below EMA 50
- SMA 200
- $1.32
- Price below SMA 200
- EMA 200
- $1.33
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Strong Sell0
Sell0
Hold0
Buy2
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
18M12M6M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
144M95M47M0
Revenue to Profit
2025$1.5M
Revenue$0.0
Cost of revenue$1.5M
Gross profit$0.0
Operating expenses$-63.1M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Milestone Pharmaceuticals Q2 Earnings Call Highlights
MISTAugust 12, 2026
MarketBeat
Milestone Pharmaceuticals Q2 Earnings Call Highlights
MIST

Zacks Investment Research
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
MISTAugust 12, 2026
Zacks Investment Research
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
MIST

Zacks Investment Research
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
MISTJuly 29, 2026
Zacks Investment Research
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
MIST

MarketBeat
Milestone Pharmaceuticals Q1 Earnings Call Highlights
MISTMay 13, 2026
MarketBeat
Milestone Pharmaceuticals Q1 Earnings Call Highlights
MIST

Zacks Investment Research
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
MISTMay 13, 2026
Zacks Investment Research
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
MIST

Zacks Investment Research
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
MISTJanuary 27, 2026
Zacks Investment Research
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
MIST

Stocktwits
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns
MISTDecember 15, 2025
Stocktwits
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns
MIST
About Milestone Pharmaceuticals Inc. Common Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees38
CEOMr. Joseph G. Oliveto M.B.A.
IPO DateMay 9, 2019
HeadquartersMontreal, QC
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph G. Oliveto M.B.A. | CEO, President & Executive Director | 1968 |
| Mr. Amit Hasija | CFO & Executive VP of Corporate Development | 1973 |
| Mr. Jeffrey Nelson | Chief Operating Officer | 1981 |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer | 1962 |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor & Member of Scientific Advisory Board | 1962 |
| Mr. David Sandoval | General Counsel & Chief Compliance Officer | 1978 |
| Mr. Roshan Girglani | Vice President of Marketing | — |
| Mr. Jeff Moore | Vice President of Sales | — |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor & Member of the Scientific Advisory Board | 1956 |
| Dr. Guy Rousseau | SVP of Regulatory Affairs and Quality Management | — |
Fundamentals
Valuation
Price-to-sales ratio42.21
Price-to-book value4.52
Profitability
Return on Equity-288.00%
Return on Assets-58.00%
Return on Sales-3124.00%
Gross margin (latest quarter)94.28%
EBITDA$-73.03M
Trading
Average volume964,878
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 40.73
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.03
- MACD histogram
- 0.00
- SMA 50
- $0.83
- Price below SMA 50
- EMA 50
- $0.83
- Price below EMA 50
- SMA 200
- $1.32
- Price below SMA 200
- EMA 200
- $1.33
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $3.00
- Average
- $5.50
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -21.3 | +16.1 | ||||||||||
| 2022 | -3.9 | -24.4 | +31.0 | -2.9 | -8.8 | +13.3 | +27.1 | +18.6 | +4.6 | -44.7 | -2.6 | -18.5 |
| 2023 | -9.6 | -21.4 | +25.5 | -8.8 | +8.8 | -23.0 | -3.6 | -15.5 | +14.8 | -14.1 | +19.3 | -47.3 |
| 2024 | -11.1 | +0.6 | +11.2 | -9.8 | -6.3 | -12.6 | +7.5 | +2.2 | +9.4 | -3.3 | +38.2 | +18.0 |
| 2025 | -9.2 | -16.8 | -51.5 | +73.7 | +22.7 | +12.1 | -22.9 | +28.7 | +8.7 | -6.3 | +45.4 | -24.9 |
| 2026 | -6.8 | -12.8 | -31.2 | +37.4 | -24.1 | -1.5 | -15.9 | +3.6 | -23.7 | -11.0 | -8.3 |
Compare stocks
Market cap
$82.44M
-
-
-
Price / Earnings ratio
-1.00
-
-
-
Price / Sales ratio
42.21
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
964,878
-
-
-
Earnings per share
$-0.68
-
-
-



